Do incretins improve endothelial function?
Open Access
- 1 January 2014
- journal article
- review article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 13 (1) , 21
Abstract
An impaired endothelial function has been recognized in the early stage of atherosclerosis, and is a major factor affecting the future development of cardiovascular events. Type 2 diabetes mellitus (T2DM) is widely prevalent, and is one of the most important risk factors for cardiovascular disease. T2DM is associated with increases in both morbidity and mortality, particularly from cardiovascular disease.New therapies based on the incretin hormone and its actions are now becoming widely used, and appear to offer advantages over conventional therapies by keeping the body weight steady and limiting hypoglycemia, while also achieving attractive glycemic control. However, there is little data available about the effects of incretins on the cardiovascular system.This review will focus on the effects of incretin therapies, including glucagon-like peptide-1 (GLP-1) analogs and dipeptidyl peptidase (DPP)-4 inhibitors, on the endothelial function, and will discuss the potential mechanisms underlying these effects.Keywords
This publication has 60 references indexed in Scilit:
- Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent mannerCardiovascular Diabetology, 2013
- Effects of sitagliptin beyond glycemic control: focus on quality of lifeCardiovascular Diabetology, 2013
- Dipeptidyl Peptidase‐4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow‐Mediated Vasodilatation in Type 2 Diabetic PatientsJournal of the American Heart Association, 2013
- Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non- diabetic subjects: a preliminary reportCardiovascular Diabetology, 2013
- Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trialCardiovascular Diabetology, 2012
- Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 DiabetesDiabetes Care, 2011
- The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an “Endothelial Resistance” to Glucagon-Like Peptide 1 in DiabetesDiabetes Care, 2011
- Assessment of flow-mediated dilation in humans: a methodological and physiological guidelineAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Improvement of Postprandial Endothelial Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 DiabetesDiabetes Care, 2010
- Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4Diabetes, 2010